Confronting the Challenge of COPD: What Is New in the Approaches to Diagnosis, Treatment, and Patient Outcomes
Most aspects of chronic obstructive pulmonary disease (COPD) have been undergoing renewed scrutiny in recent years, with research investigating the entire spectrum of disease development and progression, the genetic phenotypes and risk factors, disease heterogeneity, refinements in diagnostic approaches, advances in treatment options, and so forth. This activity provides insights into new approaches to identifying patients with undiagnosed COPD, the importance of early initiation of pharmacologic treatment in a guideline-congruent manner, and the importance of repeated patient training in correct inhaler technique in order to improve adherence and patient outcomes.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment or management of patients with COPD.
Upon completion of this activity, participants will be better able to do the following:
- Implement steps to identify undiagnosed cases of COPD requiring treatment
- Apply guideline-recommended and evidence-based pharmacologic interventions to reduce COPD symptoms and decrease exacerbations
- Regularly counsel patients with COPD on medication adherence and inhaler techniques
MeiLan K. Han, MD, MS
Nicola A. Hanania, MD, MS
Fernando J. Martinez, MD, MS
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
MeiLan K. Han, MD, MS
Consultant/Advisor: AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline LLC, Sunovion Pharmaceuticals Inc.
Grant/Research Support: Novartis AG
Nicola A. Hanania, MD, MS
Consultant/Advisor: AstraZeneca, F. Hoffmann-La Roche Ltd, GlaxoSmithKline LLC, Novartis AG, Sanofi
Grant/Research Support: AstraZeneca, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, GlaxoSmithKline LLC
|Fernando J. Martinez, MD, MS|
Consultant/Advisor: AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline LLC, Novartis AG, Pearl Therapeutics, Inc., Theravance Biopharma
Grant/Research Support: AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline LLC
Speakers’ Bureau: AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline LLC, Novartis AGRoyalties/Patents: UpToDate, Inc.
Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from GlaxoSmithKline LLC.
Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC., and GlaxoSmithKline LLC, do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician